PMID- 31175783
OWN - NLM
STAT- MEDLINE
DCOM- 20190830
LR  - 20190830
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 72
IP  - 5 cz 1
DP  - 2019
TI  - Comparison of metabolic profile of obese non-diabetic patients with coronary 
      artery disease depending on atorvastatin dose.
PG  - 846-850
AB  - OBJECTIVE: Introduction:Cardiovascular diseases (CVD) are one of the most 
      important medical-biological and social problems in Ukraine and in the world 
      because coronary artery disease (CAD) is a major cause of death and disability. 
      Overweight and obesity are risk factor of CVD and type 2 diabetes mellitus 
      (T2DM). Although statins have been shown to be beneficial in secondary prevention 
      of CVD in a number of trials, current reports of increased risk of T2DM with 
      statin use raise concerns. The aim: To compare the metabolic profile and 
      therapeutic targets of non-diabetic obese patients with CAD depending on the dose 
      of atorvastatin. PATIENTS AND METHODS: Materials and methods: The study included 
      107 patients (82 men and 25 women) with CAD and abdominal obesity. Patients were 
      divided into two groups: those taking 20 mg and 40 mg of atorvastatin daily 
      correspondingly. Glucose, insulin, HbA1c, HOMA-IR, lipids, hs-CRP and 
      anthropometric parameters were measured for each subject. RESULTS: Results: For 
      patients with CAD and obesity, who had taken atorvastatin in a 40-mg dose, we 
      observed a significant increase in insulin resistance and impaired fasting 
      glucose. Also we found a reliable correlation between the carbohydrate and lipid 
      spectrum. These parameters reflect the mechanism of the formation of metabolic 
      disorders as a result of intensive statin therapy. CONCLUSION: capital ES, Cyrilliconclusions: 
      Despite of the beneficial reductions in LDL and total cholesterol, atorvastatin 
      treatment on a dose 40 mg resulted in significant increase of fasting glucose, 
      insulin levels and insulin resistance pertaining to those patients.
FAU - Maksymets, Tetiana
AU  - Maksymets T
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
FAU - Sorochka, Maria
AU  - Sorochka M
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
FAU - Bondarenko, Olha
AU  - Bondarenko O
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
FAU - Karpyshyn, Natalia
AU  - Karpyshyn N
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
FAU - Bochar, Olesia
AU  - Bochar O
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
FAU - Sklyarov, Yevhen
AU  - Sklyarov Y
AD  - Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Atorvastatin
MH  - *Coronary Artery Disease/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolome
MH  - Obesity
MH  - Ukraine
OTO - NOTNLM
OT  - atorvastatin
OT  - coronary artery disease
OT  - insulin resistance, small o, Cyrillicbesity, coronary artery disease, atorvastatin, type 2 
      diabetes mellitus
OT  - type 2 diabetes mellitus
EDAT- 2019/06/09 06:00
MHDA- 2019/08/31 06:00
CRDT- 2019/06/09 06:00
PHST- 2019/06/09 06:00 [entrez]
PHST- 2019/06/09 06:00 [pubmed]
PHST- 2019/08/31 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2019;72(5 cz 1):846-850.